TY - JOUR
T1 - Cognitive disorders in epilepsy I
T2 - Clinical experience, real-world evidence and recommendations
AU - Kanner, Andres M.
AU - Helmstaedter, Christoph
AU - Sadat-Hossieny, Zahra
AU - Meador, Kimford
N1 - Funding Information:
Dr Meador has received research support from the N ational Institutes of Health and Sunovion Pharmaceuticals, and travel support from Eisai. The Epilepsy Study Consortium pays Dr Meador’s university for his research consultant time related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, and UCB Pharma.
Funding Information:
Dr. Helmstaedter reports grants from EU Grant E-Epilepsy, personal fees and non-financial support from UCB, personal fees from EISAI, non-financial support from Desitin Pharma, personal fees from GW-Pharma, grants from E piCare European Network (ERN), personal fees from Precisis AG, outside the submitted work; In addition, Dr. Helmstaedter has a patent Trade Mark EpiTrack® with royalties paid.
Funding Information:
Dr Meador has received research support from the National Institutes of Health and Sunovion Pharmaceuticals, and travel support from Eisai. The Epilepsy Study Consortium pays Dr Meador's university for his research consultant time related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, and UCB Pharma.Dr. Helmstaedter reports grants from EU Grant E-Epilepsy, personal fees and non-financial support from UCB, personal fees from EISAI, non-financial support from Desitin Pharma, personal fees from GW-Pharma, grants from EpiCare European Network (ERN), personal fees from Precisis AG, outside the submitted work; In addition, Dr. Helmstaedter has a patent Trade Mark EpiTrack? with royalties paid.
Publisher Copyright:
© 2020 British Epilepsy Association
PY - 2020/12
Y1 - 2020/12
N2 - This is the first of two narrative reviews on cognitive disorders in epilepsy (companion publication : Cognitive disorders in epilepsy II: Clinical targets, indications and selection of test instruments). Its focus is on clinical experience, real-world evidence, and clinical recommendations. Cognitive disorders are a common comorbidity in children and adults with epilepsy. These cognitive disturbances may preceed the onset of seizures and are multifactorial including contributions by pre-existing brain damage, seizures, interictal epileptic discharges, and treatments including medications and surgery. Comorbid cognitive impairments can have a negative impact on the quality of life in people with epilepsy. They are under-identified and frequently not treated. Comorbid psychiatric disorders, such as ADHD can also contribute to a worse cognitive performance and can benefit from pharmacotherapy with CNS stimulants. Likewise, mood disorders cause a subjective perception of poor memory and attention, which can be reversed with antidepressants of the SSRI family. This narrative review discusses these issues from a real-world clinical perspective in children and adults with newly diagnosed and chronic epilepsy. The need for further research to understand and treat these disorders is noted.
AB - This is the first of two narrative reviews on cognitive disorders in epilepsy (companion publication : Cognitive disorders in epilepsy II: Clinical targets, indications and selection of test instruments). Its focus is on clinical experience, real-world evidence, and clinical recommendations. Cognitive disorders are a common comorbidity in children and adults with epilepsy. These cognitive disturbances may preceed the onset of seizures and are multifactorial including contributions by pre-existing brain damage, seizures, interictal epileptic discharges, and treatments including medications and surgery. Comorbid cognitive impairments can have a negative impact on the quality of life in people with epilepsy. They are under-identified and frequently not treated. Comorbid psychiatric disorders, such as ADHD can also contribute to a worse cognitive performance and can benefit from pharmacotherapy with CNS stimulants. Likewise, mood disorders cause a subjective perception of poor memory and attention, which can be reversed with antidepressants of the SSRI family. This narrative review discusses these issues from a real-world clinical perspective in children and adults with newly diagnosed and chronic epilepsy. The need for further research to understand and treat these disorders is noted.
KW - Anticonvulsants
KW - Cognition
KW - Epilepsy
KW - Epilepsy surgery
KW - Neuropsychology
UR - http://www.scopus.com/inward/record.url?scp=85094590292&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094590292&partnerID=8YFLogxK
U2 - 10.1016/j.seizure.2020.10.009
DO - 10.1016/j.seizure.2020.10.009
M3 - Review article
C2 - 33127274
AN - SCOPUS:85094590292
VL - 83
SP - 216
EP - 222
JO - Seizure : the journal of the British Epilepsy Association
JF - Seizure : the journal of the British Epilepsy Association
SN - 1059-1311
ER -